Natixis Advisors LLC Trims Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Natixis Advisors LLC cut its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 520,002 shares of the medical equipment provider’s stock after selling 6,807 shares during the quarter. Natixis Advisors LLC owned approximately 0.15% of Intuitive Surgical worth $271,421,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ISRG. Atala Financial Inc acquired a new stake in Intuitive Surgical in the fourth quarter valued at approximately $25,000. Berbice Capital Management LLC purchased a new position in shares of Intuitive Surgical in the fourth quarter worth $26,000. BankPlus Trust Department purchased a new position in shares of Intuitive Surgical in the fourth quarter worth $28,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Intuitive Surgical in the fourth quarter worth $31,000. Finally, MidAtlantic Capital Management Inc. purchased a new position in shares of Intuitive Surgical in the third quarter worth $33,000. 83.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on ISRG. JPMorgan Chase & Co. raised their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Barclays raised their target price on shares of Intuitive Surgical from $610.00 to $674.00 in a report on Monday, January 27th. Citigroup raised their target price on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Evercore ISI lifted their price objective on shares of Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. Finally, UBS Group lifted their price objective on shares of Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a report on Monday, January 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average price target of $613.10.

Insiders Place Their Bets

In other news, EVP Brian Edward Miller sold 8,900 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $485.07, for a total transaction of $4,317,123.00. Following the completion of the transaction, the executive vice president now owns 5,758 shares of the company’s stock, valued at $2,793,033.06. This represents a 60.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Robert Desantis sold 11,545 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $499.22, for a total value of $5,763,494.90. Following the sale, the executive vice president now owns 5,224 shares of the company’s stock, valued at $2,607,925.28. The trade was a 68.85 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,754 shares of company stock worth $17,691,621. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Trading Up 1.6 %

Shares of ISRG opened at $484.44 on Friday. The stock has a market cap of $172.55 billion, a P/E ratio of 75.58, a PEG ratio of 5.85 and a beta of 1.43. The company has a 50-day moving average of $567.46 and a two-hundred day moving average of $531.26. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.